KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Idexx Laboratories (IDXX) over the last 16 years, with Dec 2024 value amounting to -$878.1 million.

  • Idexx Laboratories' Cash from Financing Activities fell 7.67% to -$313.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 39.47%. This contributed to the annual value of -$878.1 million for FY2024, which is 98.66% down from last year.
  • According to the latest figures from FY2024, Idexx Laboratories' Cash from Financing Activities is -$878.1 million, which was down 98.66% from -$442.0 million recorded in FY2023.
  • In the past 5 years, Idexx Laboratories' Cash from Financing Activities ranged from a high of -$248.4 million in FY2020 and a low of -$878.1 million during FY2024.
  • For the 3-year period, Idexx Laboratories' Cash from Financing Activities averaged around -$563.7 million, with its median value being -$442.0 million (2023).
  • As far as peak fluctuations go, Idexx Laboratories' Cash from Financing Activities slumped by 180.74% in 2021, and later skyrocketed by 46.81% in 2022.
  • Idexx Laboratories' Cash from Financing Activities (Yearly) stood at -$248.4 million in 2020, then slumped by 180.74% to -$697.4 million in 2021, then surged by 46.81% to -$370.9 million in 2022, then fell by 19.16% to -$442.0 million in 2023, then crashed by 98.66% to -$878.1 million in 2024.